Sanofi to Post Q2 2024 Earnings of $0.91 Per Share, Leerink Partnrs Forecasts (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Leerink Partnrs decreased their Q2 2024 earnings estimates for shares of Sanofi in a research note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of $0.91 per share for the quarter, down from their prior forecast of $0.93. The consensus estimate for Sanofi’s current full-year earnings is $4.15 per share. Leerink Partnrs also issued estimates for Sanofi’s Q3 2024 earnings at $1.30 EPS, Q4 2024 earnings at $0.82 EPS, FY2026 earnings at $4.78 EPS and FY2027 earnings at $5.00 EPS.

A number of other equities analysts have also recently commented on the stock. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Morgan Stanley began coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. Finally, TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $55.00.

Sanofi Price Performance

SNY stock opened at $45.39 on Friday. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average price of $47.52 and a 200 day moving average price of $48.67. The stock has a market cap of $114.82 billion, a PE ratio of 19.23, a P/E/G ratio of 1.72 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The firm had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion.

Institutional Investors Weigh In On Sanofi

Several hedge funds have recently modified their holdings of the business. SRS Capital Advisors Inc. raised its stake in shares of Sanofi by 289.1% during the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock worth $25,000 after acquiring an additional 344 shares in the last quarter. Householder Group Estate & Retirement Specialist LLC acquired a new position in Sanofi during the 3rd quarter valued at approximately $26,000. Fairfield Bush & CO. acquired a new position in Sanofi during the 1st quarter valued at approximately $26,000. Rise Advisors LLC increased its stake in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares in the last quarter. Finally, Salem Investment Counselors Inc. acquired a new position in Sanofi during the 4th quarter valued at approximately $27,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a $1.478 dividend. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is presently 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.